Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor
- PMID: 21180512
- PMCID: PMC3002487
- DOI: 10.1177/1756283X08093607
Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor
Abstract
Colorectal cancer is a prevalent disease in Western countries. While prevention through screening is the best approach to combat the development of colorectal cancer through the removal of precursor adenomas, many patients present with advanced disease that will require surgery and systemic therapy to improve survival. With reference to systemic therapy, the median survival of patients with metastatic colorectal cancer (those with tumor spread to lymph nodes or distant sites) has improved over the past three decades due to the introduction of 5-fluorouracil (5-FU), its subsequent biomodulation, and the addition other chemotherapeutic agents. There is now evidence that the biology of the colorectal tumor, in addition to the stage of colorectal cancer, may predict response to 5-FU-based therapy. More recently, systemic biological therapies that target signaling processes for tumor growth, such as epidermal growth factor receptor, and vascular endothelial growth factor, are also effective in improving patient survival with metastatic colorectal cancer. The use of a combination of systemic therapies that include chemotherapy and biologic therapy should continue to increase patient survival with metastatic colorectal cancer through appropriately designed clinical trials. Treatments based on the biology of the colorectal tumor also need to be examined through clinical trials.
Keywords: 5-fluorouracil; bevacizumab; biologic therapy; cetuximab; chemotherapy; colorectal cancer; epidermal growth factor receptor; tyrosine kinase inhibitor; vascular endothelial growth factor.
Figures

Similar articles
-
Integration of novel agents in the treatment of colorectal cancer.Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. doi: 10.1007/s00280-004-0884-0. Cancer Chemother Pharmacol. 2004. PMID: 15309512 Review.
-
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1. Ont Health Technol Assess Ser. 2010. PMID: 23074403 Free PMC article.
-
Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Drugs R D. 2011. PMID: 21679003 Free PMC article. Review.
-
Advances in chemotherapy against advanced or metastatic colorectal cancer.Digestion. 2008;77 Suppl 1:13-22. doi: 10.1159/000111483. Epub 2008 Jan 18. Digestion. 2008. PMID: 18204257 Review.
-
New oxaliplatin-based combinations in the treatment of colorectal cancer.Colorectal Dis. 2003 Nov;5 Suppl 3:1-9. doi: 10.1046/j.1463-1318.5.s3.2.x. Colorectal Dis. 2003. PMID: 23573555 Review.
Cited by
-
Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.Oncogenesis. 2016 Jul 18;5(7):e242. doi: 10.1038/oncsis.2016.51. Oncogenesis. 2016. PMID: 27429074 Free PMC article.
-
Curcumin Loaded Nanocarriers with Varying Charges Augmented with Electroporation Designed for Colon Cancer Therapy.Int J Mol Sci. 2022 Jan 26;23(3):1377. doi: 10.3390/ijms23031377. Int J Mol Sci. 2022. PMID: 35163301 Free PMC article.
-
Metformin and ICG-001 Act Synergistically to Abrogate Cancer Stem Cells-Mediated Chemoresistance in Colorectal Cancer by Promoting Apoptosis and Autophagy.Cancers (Basel). 2022 Mar 2;14(5):1281. doi: 10.3390/cancers14051281. Cancers (Basel). 2022. PMID: 35267590 Free PMC article.
-
Synergistic antitumor effect of 5-fluorouracil with the novel LSD1 inhibitor ZY0511 in colorectal cancer.Ther Adv Med Oncol. 2020 Jul 23;12:1758835920937428. doi: 10.1177/1758835920937428. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32754230 Free PMC article.
-
5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.Nat Commun. 2020 Oct 21;11(1):5321. doi: 10.1038/s41467-020-19173-2. Nat Commun. 2020. PMID: 33087710 Free PMC article.
References
-
- Arnold C.N., Goel A., Boland C.R. (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluoruracil in colorectal cancer cell lines, Int J Cancer 106:66–73 - PubMed
-
- Best L., Simmonds P., Baughan C., Buchanan R., Davis C., Fentiman I.et al. (2000) Colorectal meta-analysis Collaboration. Palliative chemotherapy for advanced or metastatic colorectal cancer, Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001545. 10.1002/14651858.CD001545 Accessed April 8, 2008 - DOI - PMC - PubMed
-
- Boland C.R., Sinicrope F.A., Brenner D.E., Carethers J.M. (2000) Colorectal cancer prevention and treatment, Gastroenterology 118:S115–S128 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous